Actualités

Tempus AI, a healthcare tech company, is a favorite of investor Cathie Wood. Personalis does cancer testing.

Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.

Tempus AI (TEM) has agreed to acquire Personalis (PSNL) in a deal with a total enterprise value of $

Personalis stock popped Friday on a rumor Merck and at least two other suitors are trying to buy the small genomics company.

Cathie Wood's Ark Genomic Revolution ETF owns $50 million worth of Recursion Pharmaceuticals stock.

Editor’s Note: This story has been updated to correct details related to Intel (INTC). When it comes to tracking the trading activity of members of Congress, former Speaker of the House Nancy Pelosi (D-Calif.) has been among the most followed....

Tempus AI, Inc. (NASDAQ:TEM) is one of the 10 Best Under-the-Radar Stocks to Invest In. On July 1, Freedom Capital initiated coverage of Tempus AI, Inc. (NASDAQ:TEM) with a Hold rating. The firm gave a $59 price target on the shares. In an investor note, the firm noted that healthcare AI remains one of the […]

Tempus AI Inc. (NASDAQ:TEM) is one of the top 10 hidden AI stocks to buy. On May 31, Tempus AI launched the next generation of Lens, an agentic AI platform designed to accelerate oncology drug development. By integrating Tempus’ massive library of longitudinal real-world data, oncology foundation models, and computational infrastructure, the platform provides an […]

Tempus AI Inc. (NASDAQ:TEM) is one of BlackRock’s 30 most important AI stocks right now. BlackRock holds a 5.14% stake in the company, with 8.97 million shares as of March 31, 2026. However, Cathie Wood’s ARK Investment Management controls a slightly higher stake at 5.51%, making BlackRock the second-largest institutional holder. Tempus became an investor […]

By Karen Roman CareDx, Inc. (Nasdaq: CDNA) said it completed the acquisition of Naveris, which includes its leading product, NavDx, a blood-based test for viral-mediated cancer detection including human papillomavirus, and associated head and neck and anal cancers. NavDx is the first and only Medicare-covered test for HPV-driven head and neck and anal cancer molecular […] The post CareDx Acquires Naveris, Extends Leadership into High-Growth Specialty Oncology appeared first on ExecEdge.

Tempus AI stock has jumped 18.6% over the past week, yet the valuation picture is mixed, with a Discounted Cash Flow (DCF) intrinsic value estimate pointing to meaningful upside while the broader checks suggest the shares are not a clear bargain. The 18.6% gain in the past week signals that expectations around Tempus AI have been reset quickly. This can leave new buyers with less room for error if sentiment cools. Strong revenue growth and expanding data and AI partnerships can support long...

Tempus AI recently announced a research collaboration with Angiosarcoma Awareness, Inc. to apply its approximately 600 de-identified, molecularly sequenced angiosarcoma records and analytical resources to deepen understanding of this rare and aggressive cancer. This partnership creates one of the largest known angiosarcoma molecular datasets, offering researchers a more comprehensive view of disease biology and potential therapeutic opportunities that are hard to see in smaller, fragmented...

Freedom Capital initiated Tempus AI with a Hold rating and $59 price target, saying valuation looks “about right.

The biggest long-term winners of the AI revolution may be the companies supplying the compute, power, cooling, deployment, and data infrastructure that every AI model depends on.

Cathie Wood Loads Up on AI Winners as She Cuts Roku and China Exposure

Tempus AI's stock has hit a rough patch, but fundamentals remain solid. What does it mean for investors?

Congresswoman and former Speaker of the House Nancy Pelosi (D-Calif.) is one of the most followed members of Congress when it comes to her disclosed stock and options trades. Here’s a look at the trades disclosed by Pelosi since the...

Tempus AI Inc. (NASDAQ:TEM) is one of the 10 worst artificial intelligence stocks under $30 according to short sellers. During the first week of June, Tempus AI Inc. (NASDAQ:TEM) shared the impending clinical availability for its advanced sequencing test, xH. It detects oncologic targets within bone marrow and peripheral blood samples, based on whole-genome sequencing […]

Tempus AI, Inc. (NASDAQ:TEM) is one of the 12 Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On. On June 11, 2026, Tempus AI, Inc. (NASDAQ:TEM) announced that a multi-center validation of its artificial intelligence ECG software for predicting one-year atrial fibrillation or flutter risk was published in Heart Rhythm. The company stated the […]

We just covered the 10 Stocks That Will 10X According to Social Media. Tempus AI (NASDAQ:TEM) ranks #7 (see 5 Stocks That Will 10X According to Social Media). Number of Hedge Fund Investors: 33 Tempus AI (NASDAQ:TEM) runs cancer diagnostic tests and sells the resulting data and AI tools to pharmaceutical companies and research institutions. […]

Tempus AI, Inc. (NASDAQ:TEM) is one of the 8 Best Genomics Stocks to Buy According to Analysts. On June 3, Tempus AI, Inc. (NASDAQ:TEM) reported that it launched an open-source digital pathology consortium, alongside Yale New Haven Hospital and Memorial Sloan Kettering Cancer Center, aiming to build a scalable platform and viewer. Chief of Pathology […]

Wondering if Tempus AI at around US$47.82 is starting to look interesting, or if the stock still carries more risk than reward for you. The stock has risen 3.0% over the past week and 4.2% over the past month, although it is still down 23.3% year to date and has fallen 32.9% over the past year. Recent coverage has focused on Tempus AI as part of the broader conversation around AI in healthcare and life sciences, with investors weighing its long term potential against ongoing execution risks...

Tempus AI Inc (NASDAQ:TEM) is one of the 12 Best Mid-Cap AI Stocks to Buy According to Analysts. On May 29, Tempus AI Inc (NASDAQ:TEM) announced that it had received FDA approval for a tumor-only indication for its xT CDx sequencing platform. This makes the company the only laboratory to have both tumor-only and tumor-normal […]

Market snapshot and recent moves Tempus AI (TEM) has drawn fresh attention after a strong single-day move, with the stock up about 10% on the latest close at US$52.26, compared with weaker returns over the past month. See our latest analysis for Tempus AI. That move comes after mixed momentum over the year, with the 7 day share price return of 1.89% set against a year to date share price decline of 16.2% and a 1 year total shareholder return that is down 10.91%. Recent strength is emerging...

Tempus AI Inc. (NASDAQ:TEM) is one of the 9 Stocks Crushing the Market With Surging Returns. Tempus AI saw its share prices jump by 10 percent on Thursday to finish at $52.56 apiece, as investors cheered its formation of a consortium alongside two health institutions to support the development of an open-source digital pathology platform […]

Tempus (TEM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Tempus AI, Inc. (NASDAQ:TEM) ranks among the best short squeeze stocks to invest in. Following the company’s first-quarter results, H.C. Wainwright reduced its price target for Tempus AI, Inc. (NASDAQ:TEM) to $64 from $95 while retaining a Buy rating on the company’s shares. Tempus AI, Inc. (NASDAQ:TEM) posted total revenue of $348.1 million in Q1, […]

In recent days, Tempus AI announced a string of oncology-focused product advances, including FDA approval of its xT CDx tumor-only sequencing assay, major upgrades to its AI-enabled Next and Hub platforms, and new tools like Preview, Lens, and the ArteraAI Prostate Test (mHSPC) that deepen its role in precision cancer care. Taken together, these moves highlight Tempus AI’s effort to turn its multimodal data and foundation models into end-to-end clinical and biopharma solutions, from faster...

Welcome to this week’s installment of “The Short Interest Report” – The Fly’s weekly recap of short interest trends among some of the most widely followed high-short-float stocks. Using the data from our partner Ortex.com, which utilizes the latest information from stock lenders to estimate short interest changes for thousands of publicly traded companies, this report will screen for some of biggest changes in short interest as a percentage of free float and days-to-cover ratios while also consi

Tempus AI’s latest analyst update keeps the fair value target unchanged at US$67.20 per share, even as model assumptions are fine tuned. The steady target sits against a mixed backdrop, where some analysts highlight long term potential tied to partnerships while others have recently cut price targets and flagged execution risk. As you read on, you will see how these differing views and incremental model tweaks shape the evolving Tempus AI story and what it could mean for your own research...